Eiger BioPharmaceuticals announced that the Food and Drug Administration (FDA) has granted Fast Track designation to lonafarnib in combination with ritonavir for treatment of hepatitis delta virus (HDV) infection.
Lonafarnib is a late stage, orally active agent targeting farnesyltransferase. Lonafarnib inhibits the prenylation step of HDV replication inside liver cells and blocks the ability of the virus to multiply. Since prenylation is carried out by a host enzyme there is also a theoretical higher barrier to develop viral resistance mutations with lonafarnib therapy.
Previously the FDA granted lonafarnib Orphan Drug designation. Lonafarnib is currently being evaluated in Phase 2 clinical trials.
For more information visit EigerBio.com.